Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 2/20 | 0.40 |
| ▸ | CNR2 | P34972 | 2/20 | 0.40 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 2/20 | 0.40 |
| ▸ | AGXT | P21549 | 2/20 | 0.40 |
| ▸ | APP | P05067 | 4/20 | 0.39 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.39 |
| ▸ | PDE10A | Q9Y233 | 6/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9987933 | 0.80 | PIN1 (0.44) | CNR1CNR2HRH4IDO1AGXT | |
| SCHEMBL9987222 | 0.80 | CNR1 (0.44) | CNR1CNR2HRH4IDO1AGXT | |
| SCHEMBL16176252 | 0.79 | ALDH1A1 (0.39) | IDO1PIN1PDE10A | |
| SCHEMBL31514820 | 0.79 | CNR1 (0.43) | CNR1CNR2HRH4IDO1AGXT | |
| SCHEMBL22323930 | 0.79 | APP (0.50) | CNR1CNR2HRH4IDO1AGXT | |
| SCHEMBL3196355 | 0.79 | CNR1 (0.43) | CNR1CNR2HRH4IDO1AGXT | |
| SCHEMBL846643 | 0.79 | POLB (0.47) | CNR1CNR2HRH4IDO1AGXT | |
| SCHEMBL9987333 | 0.77 | MAOB (0.44) | CNR1CNR2HRH4IDO1AGXT | |
| SCHEMBL20565264 | 0.77 | APP (0.36) | CNR1CNR2HRH4IDO1AGXT | |
| SCHEMBL31514736 | 0.76 | PDE10A (0.39) | CNR1CNR2HRH4PDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025092905-A1 | PARP INHIBITORS AND USES THEREOF | SUZHOU EOC MEDICAL RESEARCH CO., LTD. (CN) | 2025-05-08 | — | — | WO | disclosed |
| WO-2025091346-A1 | PARP INHIBITORS AND USES THEREOF | SUZHOU EOC MEDICAL RESEARCH CO., LTD. (CN) | 2025-05-08 | — | — | WO | disclosed |
| US-20190135793-A1 | HETEROCYCLIC INHIBITORS OF KDM5 FOR THE TREATMENT OF DISEASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2019-05-09 | — | — | US | disclosed |
| US-20190135793-A1 | HETEROCYCLIC INHIBITORS OF KDM5 FOR THE TREATMENT OF DISEASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2019-05-09 | — | — | US | disclosed |
| WO-2018213777-A1 | HETEROCYCLIC INHIBITORS OF KDM5 FOR THE TREATMENT OF DISEASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2018-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190135793-A1 | HETEROCYCLIC INHIBITORS OF KDM5 FOR THE TREATMENT OF DISEASE | KDM5A, KDM5B, KDM5C | HTR6 2859/4885CNR1 2906/4885CNR2 2908/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.